Article
Multidisciplinary Sciences
Michela Palleschi, Andrea Prochowski Iamurri, Emanuela Scarpi, Marita Mariotti, Roberta Maltoni, Francesca Mannozzi, Domenico Barone, Giovanni Paganelli, Michela Casi, Emanuela Giampalma, Ugo De Giorgi, Andrea Rocca
Summary: This study found that high baseline subcutaneous fat index and total abdominal fat index were associated with worse progression-free survival in patients with HER2-positive metastatic breast cancer receiving first-line pertuzumab/trastuzumab-based treatment.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Thomas Hatschek, Theodoros Foukakis, Judith Bjohle, Tobias Lekberg, Hanna Fredholm, Ellinor Elinder, Ana Bosch, Gyula Pekar, Henrik Lindman, Aglaia Schiza, Zakaria Einbeigi, Jamila Adra, Anne Andersson, Lena Carlsson, Ann Charlotte Dreifaldt, Erika Isaksson-Friman, Susanne Agartz, Edward Azavedo, Per Gryback, Mats Hellstrom, Hemming Johansson, Claudia Maes, Ioannis Zerdes, Johan Hartman, Yvonne Brandberg, Jonas Bergh
Summary: A randomized phase 2 trial in Sweden compared standard neoadjuvant therapy with combination DTP to T-DM1 monotherapy in ERBB2-positive breast cancer patients, showing no significant difference in treatment outcomes between the two groups.
Article
Oncology
Otto Metzger Filho, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell'Orto, Leila Russo, Tari A. King, Kornelia Polyak, Franziska Michor, Eric P. Winer, Ian E. Krop
Summary: Intratumor heterogeneity, particularly the fraction of ERBB2 nonamplified cancer cells, is strongly correlated with resistance to HER2-targeted therapies and could potentially aid in optimizing treatment selection for HER2-positive breast cancer patients.
Article
Oncology
Sheau Wen Lok, Richard De Boer, Sally Baron-Hay, Peter Button, Bianca Devitt, Benjamin C. Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E. Kiely, Gavin Marx, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter Gibbs
Summary: This study analyzed the safety and effectiveness data of pertuzumab in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia. The results revealed that pertuzumab showed effectiveness in surgical outcomes and the safety data align with previous clinical trials, without any new safety concerns.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Yuson Wang, Xiaoyan Liu, Keda Yu, Shouping Xu, Pengfei Qiu, Xinwen Zhang, Mozhi Wang, Yingying Xu
Summary: Neoadjuvant therapy (NAT) is recommended for patients with HER2+ BC who have a poor prognosis. The tumor immune microenvironment plays a significant role in the efficacy of NAT, but the relationship between tumor-infiltrating lymphocytes and the response to NAT in HER2+ BC is not yet clear. Our study classified the immune infiltration status of 295 patients into immune-rich and immune-poor phenotypes, with the immune-rich phenotype being significantly associated with pCR. We identified 10 genes that were correlated with both pCR and the immune phenotype, and constructed a generalized non-linear model that successfully predicted response to NAT.
Article
Oncology
Martine Piccart, Marion Procter, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S. Ewer, Eleonora Restuccia, Guy Jerusalem, Susan Dent, Linda Reaby, Herve Bonnefoi, Ian Krop, Tsang-Wu Liu, Tadeusz Pienkowski, Masakazu Toi, Nicholas Wilcken, Michael Andersson, Young-Hyuck Im, Ling Ming Tseng, Hans-Joachim Lueck, Marco Colleoni, Estefania Monturus, Mihaela Sicoe, Sebastien Guillaume, Jose Bines, Richard D. Gelber, Giuseppe Viale, Christoph Thomssen
Summary: The PURPOSEAPHINITY study demonstrates that adding pertuzumab to adjuvant therapy with trastuzumab and chemotherapy significantly improves invasive disease-free survival for early HER2-positive breast cancer patients. Longer follow-up is needed for a comprehensive assessment of overall survival benefits.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, Pedram Razavi, Shanu Modi, Sarat Chandarlapaty, Andrea Barrio, Rachna Malani, Ingo K. Mellinghoff, Adrienne Boire, Hannah Y. Wen, Edi Brogi, Andrew D. Seidman, Larry Norton, Mark E. Robson, Chau T. Dang
Summary: The study aimed to investigate the incidence of brain metastases in early stage HER2-positive breast cancer patients receiving HP-based neoadjuvant chemotherapy as well as survival outcomes. While patients in the pCR group had better survival outcomes, there was no significant difference in brain metastases incidence between pCR and non-pCR patients.
Review
Oncology
Paolo Tarantino, Giuseppe Curigliano, Heather A. Parsons, Nancy U. Lin, Ian Krop, Elizabeth A. Mittendorf, Adrienne Waks, Eric P. Winer, Sara M. Tolaney
Summary: Novel diagnostic and treatment tools could potentially expand the population of patients with ERBB2-positive MBC experiencing long-lasting disease response. The identification of clinical and pathologic features that predict long-term response to chemotherapy and ERBB2-blockade is crucial for identifying the optimal curable population. Trials are being conducted to confirm this paradigm shift and usher in a new era of precision therapy for breast cancer.
Article
Oncology
Yifan Xie, Siyu Wu, Ying Zhang, Jianwei Li, Miao Mo, Zhimin Shao, Guangyu Liu
Summary: The study aimed to investigate the optimal number of cycles of neoadjuvant TCH therapy for HER2-positive breast cancer patients and found no significant difference in terms of pathological complete response rate and four-year event-free survival rate between four and six cycles. Negative hormone receptor status and weekly paclitaxel were independent factors for predicting pCR. Four cycles of taxane/carboplatin-based neoadjuvant anti-HER2 therapy may be applied as an optimal treatment duration for screening high-risk HER2-positive breast cancer patients for escalation treatment.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
M. C. Liefaard, A. van der Voort, M. S. van Ramshorst, J. Sanders, S. Vonk, H. M. Horlings, S. Siesling, L. de Munck, A. E. van Leeuwen, M. Kleijn, L. Mittempergher, M. M. Kuilman, A. M. Glas, J. Wesseling, E. H. Lips, G. S. Sonke
Summary: In patients with HER2-positive breast cancer, pertuzumab significantly improved pathological complete response rates and decreased the risk of breast cancer mortality, which was not observed in other subtypes. BluePrint subtyping may be valuable in future studies to identify patients that are likely to be highly sensitive to HER2-targeting agents.
BREAST CANCER RESEARCH
(2023)
Review
Oncology
Dan Moldoveanu, Tanya L. Hoskin, Courtney N. Day, Amy K. Schulze, Matthew P. Goetz, Judy C. Boughey
Summary: This study aimed to evaluate the effectiveness of neoadjuvant chemotherapy in treating node-positive ER+/HER2- breast cancer. The results showed a high rate of pathological complete response in the lymph nodes, which was associated with patient age and Ki67 levels. Pathological complete response in the lymph nodes was positively correlated with overall survival.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Tomas Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, M. Vittoria Dieci, Sonia Pernas, Joaquin Gavila, Valentina Guarnieri, Javier Cortes, Patricia Villagrasa, Nuria Chic, Maria Vidal, Barbara Adamo, Montserrat Munoz, Gaia Griguolo, Antonio Llombart, Pierfranco Conte, Mafalda Oliveira, Benedetta Conte, Laia Pare, Patricia Galvan, Lisa A. Carey, CharlesM. Perou, Aleix Prat
Summary: In HR+/HER2+ breast cancer, the PAM50-based CES score can predict sensitivity to chemo-endocrine therapy and provide additional prognostic information beyond intrinsic subtype and clinicopathologic characteristics. High CES is associated with lower pCR probability and better DFS.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Agnese Fabbri, Fabrizio Nelli, Andrea Botticelli, Diana Giannarelli, Eleonora Marrucci, Cristina Fiore, Antonella Virtuoso, Simone Scagnoli, Simona Pisegna, Daniele Alesini, Valentina Sini, Armando Orlandi, Alessandra Fabi, Federico Piacentini, Luca Moscetti, Giuliana D'Auria, Teresa Gamucci, Marco Mazzotta, Laura Pizzuti, Patrizia Vici, Elisabetta Cretella, Paola Scavina, Annalisa La Cesa, Mara Persano, Francesco Atzori, Enzo Maria Ruggeri, Interbreast Network
Summary: Clinical trials have shown that the addition of pertuzumab to neoadjuvant chemotherapy can significantly increase pathologic complete response in patients with early-stage HER-2 positive breast cancer. The Neopearl study aimed to assess the real-life efficacy and safety of neoadjuvant pertuzumab. The results demonstrated improved outcomes with pertuzumab, particularly in patients with positive lymph nodes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Luca Gianni, Marco Colleoni, Giancarlo Bisagni, Mauro Mansutti, Claudio Zamagni, Lucia Del Mastro, Stefania Zambelli, Giampaolo Bianchini, Antonio Frassoldati, Ilaria Maffeis, Pinuccia Valagussa, Giuseppe Viale
Summary: This study investigates the resistance to endocrine therapy in HER2- and hormone receptor-positive breast cancer, and finds that dual HER2 blockade and palbociclib can significantly decrease Ki67 expression and achieve high objective response rate and pathological complete response. The addition of fulvestrant in the treatment regimen also shows similar therapeutic effects.
Article
Oncology
Adrienne G. Waks, Esther R. Ogayo, Laia Pare, Mercedes Marin-Aguilera, Fara Braso-Maristany, Patricia Galvan, Oleguer Castillo, Olga Martinez-Saez, Ana Vivancos, Patricia Villagrasa, Guillermo Villacampa, Paolo Tarantino, Neelam Desai, Jennifer Guerriero, Otto Metzger, Nadine M. Tung, Ian E. Krop, Joel S. Parker, Charles M. Perou, Aleix Prat, Eric P. Winer, Sara M. Tolaney, Elizabeth A. Mittendorf
Summary: This study suggests that the HER2DX pCR score assay can predict the likelihood of pathologic complete response (pCR) in patients with early-stage ERBB2+ breast cancer who receive deescalated neoadjuvant therapy. The HER2DX pCR score could guide treatment decisions by identifying patients who are candidates for either deescalated or escalated approaches.
Article
Oncology
Anouk H. Eijkelboom, Linda de Munck, C. Willemien Menke-van der Houven Van Oordt, Mireille J. M. Broeders, Desiree H. J. G. van den Bongard, Luc J. A. Strobbe, Marc A. M. Mureau, Marc B. Lobbes, Pieter J. Westenend, Linetta B. Koppert, Agnes Jager, Ester J. M. Siemerink, Jelle Wesseling, Helena M. Verkooijen, Marie-Jeanne T. F. D. Vrancken Peeters, Marjolein L. Smidt, Vivianne C. G. Tjan-Heijnen, Sabine Siesling
Summary: This study compared the treatments and time intervals between treatments of breast cancer patients diagnosed during and before the COVID-19 pandemic, and the number of treatments started during and before the pandemic. The results showed that patients diagnosed during the transition period were less likely to receive neo-adjuvant chemotherapy for stage I, stage II, and hormone receptor+/HER2- tumors compared to 2018/2019. The time between diagnosis and first treatment decreased for patients diagnosed during the lockdown period. Additionally, there was an increase in the number of neo-adjuvant endocrine therapies and surgeries starting in week 14 of 2020, while the number of adjuvant chemotherapies decreased in week 15 and increased in week 22.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Ariane A. van Loevezijn, Hillegonda A. O. Winter-Warnars, Genevieve S. Hernandez, Christiaan M. de Bloeme, Frederieke H. van Duijnhoven, Marie-Jeanne T. F. D. Vrancken Peeters
Summary: This study retrospectively selected early-stage breast cancer patients who underwent neoadjuvant systemic therapy (NST) and found that MRI could detect additional lesions in some patients, which could impact surgical treatment. Among them, 31% of patients had lesions detected in the ipsilateral breast, and 26% of patients underwent more extensive surgery after the detection of lesions on MRI.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Ariane A. A. van Loevezijn, Charissa S. S. Geluk, Marieke J. J. van den Berg, Erik D. D. van Werkhoven, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke H. H. van Duijnhoven, Marije J. J. Hoornweg
Summary: This study aimed to evaluate the surgical outcomes of immediate and delayed oncoplastic surgery (OPS). The study found that selecting delayed OPS allowed for re-excision of margins without dismantling the reconstruction, achieving excellent breast conservation rates.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Nansi Maliko, Thomas Schok, Nina Bijker, Michel W. J. M. Wouters, Luc J. A. Strobbe, Marije J. Hoornweg, Marie-Jeanne T. F. D. Vrancken Peeters
Summary: OPBCS is a major part of daily clinical practice of Dutch breast surgeons treating BC patients. A clear definition and standardization is necessary to improve the quality of BC care.
Article
Surgery
Babette E. Becherer, Erik A. Heeg, Danny A. Young-Afat, Marie-Jeanne T. F. D. Vrancken Peeters, Hinne A. Rakhorst, Marc A. M. Mureau
Summary: In this population-based study in the Netherlands, the incidence of unplanned revision surgery was lower in immediate implant-based breast reconstruction using a direct-to-implant approach compared to a two-stage approach. Additionally, more breasts were reconstructed within the planned number of operations in the direct-to-implant group.
PLASTIC AND RECONSTRUCTIVE SURGERY
(2023)
Article
Public, Environmental & Occupational Health
Jonathan Spoor, Marc A. M. Mureau, Juliette Hommes, Hinne Rakhorst, Anneriet E. Dassen, Hester S. A. Oldenburg, Yvonne L. J. Vissers, Esther M. Heuts, Linetta B. Koppert, Laura H. Zaal, Rene R. W. J. van der Hulst, Marie-Jeanne T. F. D. Vrancken Peeters, Eveline M. A. Bleiker, Flora E. van Leeuwen
Summary: This article introduces the Areola study, which aims to assess the risks of breast implant illness (BII) and autoimmune diseases in Dutch breast cancer survivors with silicone breast implants. The study design includes a retrospective cohort of breast cancer survivors who underwent implant-based reconstruction surgery between 2000 and 2015 in six major hospitals in the Netherlands. A comparison group of breast cancer survivors without breast implants and a group of women who received breast augmentation surgery will also be included. The study will collect data through a web-based questionnaire and link it with population-based databases to evaluate the prevalence, incidence, and risk factors of BII and autoimmune disorders.
ANNALS OF EPIDEMIOLOGY
(2023)
Editorial Material
Oncology
Annemiek K. E. van Hemert, Frederieke H. van Duijnhoven, Ariane A. van Loevezijn, Claudette E. Loo, Terry Wiersma, Emilie J. Groen, Marie-Jeanne T. F. D. Vrancken Peeters
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Annemiek K. E. van Hemert, Frederieke H. H. van Duijnhoven, Ariane A. A. van Loevezijn, Claudette E. E. Loo, Terry Wiersma, Emilie J. J. Groen, Marie-Jeanne T. F. D. Vrancken Peeters
Summary: The study aims to assess the residual disease in patients who had a favorable response on MRI and no residual disease detected through biopsy after neoadjuvant systemic treatment (NST) for breast cancer. The findings showed that substantial residual invasive disease remains in all molecular subtypes, suggesting the need for surgical excision until better imaging and biopsy techniques are developed.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Annemiek K. E. van Hemert, Josefien P. P. van Olmen, Liesbeth J. J. Boersma, John H. H. Maduro, Nicola S. S. Russell, Jolien Tol, Ellen G. G. Engelhardt, Emiel J. Th. Rutgers, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke H. H. van Duijnhoven
Summary: The purpose of this study is to show that omitting adjuvant radiotherapy in breast cancer patients with pCR after NST can result in low rates of local recurrence and good quality of life.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Marte C. C. Liefaard, Kat S. S. Moore, Lennart Mulder, Daan van den Broek, Jelle Wesseling, Gabe S. S. Sonke, Lodewyk F. A. Wessels, Matti Rookus, Esther H. H. Lips
Summary: Studies focused on using blood platelets (TEPs) to detect breast cancer were conducted, but the results were not reproducible in an independent validation cohort. Two classifiers based on TEPs reached an AUC of 0.85 in internal validation, but the AUC dropped to 0.55 and 0.54 in the independent validation set. Post hoc analyses revealed that gene expression variance was associated with the hospital where the samples were collected. The TEP protocol needs revision before it can be reconsidered for breast cancer detection.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Walter P. Weber, Oreste Davide Gentilini, Monica Morrow, Giacomo Montagna, Jana de Boniface, Florian Fitzal, Lynda Wyld, Isabel T. Rubio, Zoltan Matrai, Tari A. King, Ramon Saccilotto, Viviana Galimberti, Nadia Maggi, Mariacarla Andreozzi, Virgilio Sacchini, Liliana Castrezana Lopez, Julie Loesch, Fabienne D. Schwab, Ruth Eller, Martin Heidinger, Martin Haug, Christian Kurzeder, Rosa Di Micco, Maggie Banys-Paluchowski, Nina Ditsch, Yves Harder, Regis R. Paulinelli, Cicero Urban, John Benson, Vesna Bjelic-Radisic, Shelley Potter, Michael Knauer, Marc Thill, Marie-Jeanne Vrancken Peeters, Sherko Kuemmel, Joerg Heil, Bahadir M. Gulluoglu, Christoph Tausch, Ursula Ganz-Blaettler, Jane Shaw, Peter Dubsky, Philip Poortmans, Orit Kaidar-Person, Thorsten Kuehn, Michael Gnant
Summary: The aim of this study was to address uncertainties and controversies in axillary management of early breast cancer and make appropriate recommendations through a global consensus panel. By using the Delphi method, 15 questions were prioritized by over 250 breast surgeons, patient advocates, and radiation oncologists from 60 countries. The panel agreed on prioritizing research based on current evidence and updating recommendations as ongoing studies provide more data.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
A. Vera de Jonge, Erik van Werkhoven, Avinash G. Dinmohamed, Marcel Nijland, Aeilko H. Zwinderman, Patrick M. Bossuyt, Martine S. Veldhuis, Emma G. G. M. Rutten, Rogier Mous, Joost S. P. Vermaat, Yorick Sandberg, Eva de Jongh, Yavuz M. Bilgin, Rinske Boersma, Harry Koene, Marie Jose Kersten, Daphne de Jong, Martine E. D. Chamuleau
Summary: In a study conducted in the Netherlands, researchers found that R2CHOP treatment significantly improved the prognosis of DLBCL patients compared to R-CHOP treatment, based on a non-randomized risk-adjusted comparison.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Dinusha Veluponnar, Lisanne L. de Boer, Freija Geldof, Lynn-Jade S. Jong, Marcos Da Silva Guimaraes, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke van Duijnhoven, Theo Ruers, Behdad Dashtbozorg
Summary: During breast-conserving surgeries, accurate evaluation of tumor margins is challenging, leading to potential need for additional surgery or boost radiotherapy. The use of computer-aided delineation of tumor boundaries in ultrasound images shows promising results in predicting positive and close margins. There is a clinical need for an accurate and rapid margin assessment tool, and computer-aided ultrasound evaluation offers a potential solution.
Article
Urology & Nephrology
Hielke M. de Vries, Sarah R. Ottenhof, Tynisha S. Rafael, Erik van Werkhoven, Floris J. Pos, Bas W. G. van Rhijn, Luc M. F. Moonen, Niels Graafland, Jeantine M. de Feijter, Eva E. Schaake, Simon Horenblas, Oscar R. Brouwer
Summary: A retrospective analysis of 228 patients with penile cancer who underwent pelvic lymph node treatment showed a high recurrence rate and poor prognosis after pelvic treatment, emphasizing the need for more effective systemic treatment strategies.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)